Cogent Biosciences Inc at JPMorgan Healthcare Conference Transcript
&-
Yes already, um, welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined my squad, Malcolm, Kunal, [Ray Hall] Priyanka Grover, our next presenting company is Cogent Biosciences. And presenting on behalf of the company, we have CEO, Andy Robbins.
Great. Thanks, Anupam, for inviting us to the meeting. It's great to be here, and I'm looking forward to the presentations and Q&A today. So before I dive in just sort of remind folks that I'll probably be making some forward-looking statements today, and I would point you to our recent SEC filings for a more thorough assessment of risk associated with the company.
So I encourage you to review those. I'm going to start in use today is kind of a jumping off your beginning recap and sort of level setting for the company and especially your lead asset. So Cogent is a precision
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
